RT Journal Article
SR Electronic
T1 Higher Frequency and Mortality Rate of Antimicrobial-resistant Bloodstream Infections in Tertiary-care Hospitals Compared with Secondary-care Hospitals in Thailand
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.07.23285611
DO 10.1101/2023.02.07.23285611
A1 Lim, Cherry
A1 Hantrakun, Viriya
A1 Klaytong, Preeyarach
A1 Rangsiwutisak, Chalida
A1 Tangwangvivat, Ratanaporn
A1 phiancharoen, Chadaporn
A1 Doung-ngern, Pawinee
A1 Kripattanapong, Somkid
A1 Hinjoy, Soawapak
A1 Yingyong, Thitipong
A1 Rojanawiwat, Archawin
A1 Unahalekhaka, Aekkawat
A1 Kamjumphol, Watcharaporn
A1 Khobanan, Kulsumpun
A1 Leethongdee, Phimrata
A1 Lorchirachoonkul, Narisorn
A1 Khusuwan, Suwimon
A1 Siriboon, Suwatthiya
A1 Chamnan, Parinya
A1 Vijitleela, Amornrat
A1 Fongthong, Traithep
A1 Noiprapai, Krittiya
A1 Boonyarit, Phairam
A1 Srisuphan, Voranadda
A1 Sartorius, Benn
A1 Stelling, John
A1 Turner, Paul
A1 Day, Nicholas PJ
A1 Limmathurotsakul, Direk
YR 2023
UL http://medrxiv.org/content/early/2023/03/21/2023.02.07.23285611.abstract
AB There are few studies comparing proportion, frequency, mortality and mortality rate of antimicrobial-resistant (AMR) bacterial infections between tertiary-care hospitals (TCHs) and secondary-care hospitals (SCHs) in low and middle-income countries (LMICs) to inform infection control strategies. We evaluated bloodstream infections (BSIs) from 2012 to 2015 in 15 TCHs and 34 SCHs in Thailand. There were differences in the proportions (%) of BSI caused by AMR strains for some pathogens between TCHs and SCHs. Of 19,665 patients with AMR BSI, 6,746 (34.3%) died. Among patients with AMR BSI, there were no or minimal differences in mortality proportion for all AMR pathogens between TCHs and SCHs. However, the frequency and mortality rates of AMR BSI were considerably higher in TCHs for most pathogens. For example, the mortality rate of hospital-origin carbapenem-resistant Acinetobacter baumannii BSI in TCHs was nearly three times higher than that in SCHs (10.2 vs. 3.6 per 100,000 patient-days at risk, mortality rate ratio 2.77; 95% confidence interval 1.71 to 4.48, p<0.0001). Targets of and resources for antimicrobial stewardship and infection control programs in LMICs may need to be tailored based on hospital type and size, as burden of AMR infections could differ by hospital setting.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by the DDC, MoPH, Thailand, and Defense Threat Reduction Agency (DTRA), U.S.. This research was funded in part by the Wellcome Trust [224681/Z/21/Z and Wellcome Trust Institutional Translational Partnership Award-MORU]. BS is supported by a grant from the UK Department of Health and Social Care using UK aid funding managed by the Fleming Fund (R52354 CN001). For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally located at: https://figshare.com/s/c028f157c18a3cc06a82. Ethical permission for this study was obtained from the Institute for the Development of Human Research Protection, Ministry of Public Health (IHRP 2334/2556), the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University (MUTM 2014-017-01), and the Oxford Tropical Research Ethics Committee, University of Oxford (OXTREC 521-13). Written approval was given by the directors of the hospitals to use their routine hospital admission database for research.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript https://figshare.com/s/c028f157c18a3cc06a82